# 2026-06-26 UCB CEO Tellier / China Drug Innovation — SHIPPED

**Article:** `news/2026-06-26-ucb-china-drug-innovation-tellier-30th-anniversary-suzhou.html`
**Commit:** `46e886b`
**Live URL:** https://chinahospitalsguide.com/news/2026-06-26-ucb-china-drug-innovation-tellier-30th-anniversary-suzhou.html (HTTP 200 verified)
**Cron run:** 2026-06-26 (clean fresh research → shipped, no recovery state)

## Tool-call budget

~14 tool calls total — well under the 35-call ceiling:
1. Pre-flight: `ls news/$(date)+.html` + `git status` + `git remote -v` (clean)
2. Bing News search for "China NMPA approval drug 2026 June" → 18 external URLs surfaced
3. Bing News refined search for "silevimig rabies bispecific" → confirmed Manila Times URL
4. The Star (Malaysia) fetch for thestar.com.my 2026-06-26 healthcare-evolution article (415KB, date verified)
5. Body extraction of thestar article → 7500 chars of substantive prose
6. De-dup grep against existing `news/*.html` → 0 matches for `(Jean-Christophe Tellier|UCB.*China.*30th|China Integrated Operation Centre|one in four new drugs)` → shippable
7. Read Unixell 2026-06-25 article template scaffolding (lines 175-254)
8. `write_file` for the new article (24KB, 2,395 words)
9. Non-ASCII check → only emoji (legitimate UI)
10. Humanize score first pass → 74/100 (1 × `actually`, 1 × `pivotal`, 1 × `landscape`)
11. Patch `actually` → drop in data-box
12. Patch `landscape → picture` and `pivotal → registration` in body prose
13. Humanize score second pass → **95/100** ✓
14. Sitemap patch + index.html patch + git config + commit + push + verify (HTTP 200)

## Article angle

UCB CEO Jean-Christophe Tellier's June 26, 2026 interview with *China Daily* (syndicated via The Star / ANN): China has moved from manufacturing to clinical-trial expertise to a source of drug discovery for the rest of the world. Concrete anchors:
- **1 in 4 new drugs globally now originates in China** (Tellier's framing; could rise to 2 in 4)
- **19 of 19 NMPA innovative-drug approvals YTD 2026** are from Chinese manufacturers (15 of 19 from domestic labs)
- **76 innovative drugs approved in 2025** (record, up from 48 in 2024)
- **June 4, 2026: UCB signed Suzhou Industrial Park China Integrated Operation Centre agreement**
- **14 UCB global multi-centre clinical trials running in China simultaneously**
- **2020 Provisions for Drug Registration** fast-track pathways, expanded by May 2025 Drug Administration Law new regulations

Why shippable: the framing is the inverse of the typical "Western pharma sells to China" angle — a CEO publicly stating "China for China" is over. Cross-cuts multiple existing coverage lines (inbound medical tourism from 2026-06-22 Raffles, the new drug approvals series from 2026-06-23/24/25, and the global-trial-as-access-path angle that 2026-06-25 UniXell article introduced for cell therapy).

## Article stats

- 2,394 words, 31 em-dashes (15.5/1200 — slightly under the 17-23 baseline but well within tolerance for 2,400-word articles per the 06-09/06-15 precedent)
- Humanize score 95/100 (started 74, +21 in 2 banned-vocab patches)
- Banned vocab remaining: 0 (1 hit each of `actually`, `pivotal`, `landscape` all patched)
- Article archetype: **policy + pharma industry framing** (new variant) — closer to the 2026-06-22 Raffles operator-level angle than the cell-therapy Phase 1 / regulatory approval archetypes

## Patterns confirmed (extending the skill playbook)

- **Bing News recipe is working again on 2026-06-26** — single fetch returned 18 distinct external URLs across manilatimes.net, thestar.com.my, yahoo.com, fiercepharma.com, vir.com.vn, pharmaphorum.com, finance.yahoo.com, contractpharma.com, asiae.co.kr. 5th consecutive working run in 6 days (06-21 off-pattern was the only recent exception, per the 06-22 note).
- **The Star (Malaysia) as a Business Times/Straits Times tier source** — 415KB body, `<meta property="article:published_time" content="2026-06-26T00:00:00.000Z">` reliable, body extractable via standard `<article>` regex. Pairs well with *China Daily* syndication — the article surfaced was a *China Daily* interview, published simultaneously in the Malaysian syndication. Useful for inbound macro + pharma-industry coverage where the underlying source is *China Daily*.
- **"Pivotal → registration" / "landscape → picture" banned-vocab fix worked a 2nd time** — the same 2-line swap pattern from 2026-06-23 (CarsGen satri-cel, score 35 → 90) also worked on 2026-06-26 (score 74 → 95). For clinical/regulatory/policy articles, this is the standard 2-line fix when the only flagged words are `pivotal` + `landscape`. No need to restructure prose.
- **`actually` in body prose is tolerated at 1 hit per 4,000 words** — confirmed again on 2026-06-26. The hit was in a body sentence ("what international medical tourists can actually access in China") not in a heading, and removing it improved the score with no loss of meaning. Score impact: ~5 points.

## Recovery state for 2026-06-27

None. Article shipped, pushed, HTTP 200 verified. Working tree clean (commit `46e886b` is on origin/master). Next cron run should:
1. Run Step 0 pre-flight (expect clean state).
2. Pick a fresh 2026-06-27 topic. Candidate surface from the 06-26 Bing News grep that has NOT yet been covered:
   - **Silevimig (world's first bispecific for rabies passive immunization, NMPA approval 2026-06-22)** — Manila Times URL confirmed, niche infectious-disease angle, no current coverage in the 75-article library
   - **SystImmune Iza-bren approval (sg.finance.yahoo.com 2026-06-XX)** — bispecific ADC, oncology
   - **Hengrui ASCO 2026 follow-on coverage** (already partially covered 2026-06-20)

The silevimig story is the strongest fresh candidate: world-first designation, NMPA approval, no current site coverage, distinct from the cell-therapy and CAR-T cluster that has dominated the past 4 articles.